NCT06385106 Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
| NCT ID | NCT06385106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-03-16 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-03-16 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in Alzheimer's disease (AD), but studies on the improvement of sleep disorders in AD are limited. The aim of this study was to evaluate the effects of rTMS on sleep and cognition in patients with mild-to-moderate Alzheimer's disease (AD).
Eligibility Criteria
Inclusion Criteria: 1. Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by neuropsychology. Cerebrospinal fluid markers (Aβ40, Aβ42, T-tau, p-tau) consistent with AD, or AV-45 PET imaging showing significant cortical tracer retention, in line with AD pathophysiology. 2. Age range: 55-80 years. 3. No visual or hearing impairment. 4. Right-handed. 5. Han nationality. 6. Signed informed consent. 7. Reliable caregivers as information providers. 8. MMSE score: 10-27; CDR: 0.5-2 points. 9. If receiving approved AD treatment (e.g., acetylcholinesterase inhibitor or memantine), dose must be stable for ≥3 months prior to screening and unchanged unless medically necessary. Exclusion Criteria: 1. History of seizures or epilepsy diagnosis; 2. Stroke history; 3. Nervous system diseases causing brain dysfunction (schizophrenia, severe anxiety/depression, dementia, Huntington's, brain tumors, Parkinson's, metabolic encephalopathy, encephalitis, MS, epilepsy, brain trauma, hydrocephalus); 4. Severe liver/kidney/lung dysfunction, anemia, gastrointestinal disease, arrhythmia, recent MI; 5. Barbiturate/benzodiazepine use within 2 weeks; 6. MRI/TMS contraindications (metallic implants); 7. Systemic diseases causing cognitive impairment (hypothyroidism, folate/B12 deficiency, infections, alcohol/drug abuse); 8. Aphasia, consciousness disturbance, inability to cooperate; 9. TMS/tDCS/DBS has been processed; 10. Underlying pathology other than AD; 11. Focal brain lesions on T1/T2 images; 12. Refusal to sign informed consent.
Contact & Investigator
Benyan Luo, PhD
STUDY CHAIR
Zhejiang University
Frequently Asked Questions
Who can join the NCT06385106 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 80 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06385106 currently recruiting?
Yes, NCT06385106 is actively recruiting participants. Contact the research team at pgpfc@163.com for enrollment information.
Where is the NCT06385106 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06385106 clinical trial?
NCT06385106 is sponsored by First Affiliated Hospital of Zhejiang University. The principal investigator is Benyan Luo, PhD at Zhejiang University. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.